Difference between revisions of "WSI21-128"

From MGH Learn Pathology
(Edited automatically from page learn:wsidashboard.)
 
(141 intermediate revisions by 13 users not shown)
Line 1: Line 1:
−
{{dziOrderStudySet
+
{{ServiceRequest
−
|order_date=July 06, 2021 12:40:27 PM
+
|intent=order
−
|user=Em99
+
|category=409073007
−
|class_name=Study Set
+
|priority=routine
−
|status=Submitted
+
|code=study
−
|collection_name=Cytopathology
+
|orderDetail=order
−
|class_type=Cytology
+
|authoredOn=July 06, 2021 12:40:27 PM
−
|collection_topic=Salivary Gland
+
|requester=Em99
−
|requested_by=EMI
+
|locationCode=learn
−
|restrict_access=Public
+
|access=public
 +
|subject=MGH
 +
|performer=MGH
 +
|supportingInfo=Cytology
 +
|requisition=Cytology
 +
|reasonCode=Salivary Gland
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Si787
 +
|authoredOn=March 10, 2022 10:38:12 AM
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 17:41:28
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 17:44:46
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 18:02:06
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=May 31, 2022 18:04:43
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 10, 2022 19:40:42
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 20, 2022 13:56:31
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 20, 2022 13:56:37
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Lcm51
 +
|authoredOn=Jul 27, 2022 15:34:58
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Lcm51
 +
|authoredOn=Jul 27, 2022 15:46:56
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Tag62
 +
|authoredOn=Jul 29, 2022 12:35:26
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Mc1192
 +
|authoredOn=Jul 29, 2022 15:10:12
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Mc1192
 +
|authoredOn=Jul 29, 2022 15:13:03
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Tag62
 +
|authoredOn=Jul 29, 2022 15:41:39
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Tag62
 +
|authoredOn=Jul 29, 2022 15:41:47
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Tag62
 +
|authoredOn=Jul 29, 2022 16:12:19
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Jul 30, 2022 18:26:03
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Jul 30, 2022 18:59:11
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Jul 30, 2022 18:59:41
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Jul 30, 2022 18:59:49
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 03, 2022 15:03:04
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Aug 05, 2022 12:21:03
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Pab16
 +
|authoredOn=Aug 05, 2022 12:43:37
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 05, 2022 17:15:59
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 05, 2022 19:25:42
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 05, 2022 19:26:14
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 10, 2022 14:39:50
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Aug 10, 2022 20:41:40
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Aug 10, 2022 20:41:40
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:42:48
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 11, 2022 13:45:00
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 12, 2022 12:45:52
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Mlz8
 +
|authoredOn=Aug 12, 2022 19:14:01
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Mlz8
 +
|authoredOn=Aug 12, 2022 19:16:39
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 15, 2022 18:56:03
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 19, 2022 14:38:46
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Aug 19, 2022 14:47:52
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Sep 19, 2022 15:45:43
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Sep 19, 2022 15:47:54
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Sep 19, 2022 19:36:06
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Sep 19, 2022 19:37:26
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Sep 21, 2022 14:07:37
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Sep 21, 2022 14:13:01
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Sep 22, 2022 12:33:17
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Sep 22, 2022 20:26:08
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Sep 26, 2022 14:21:03
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Oct 03, 2022 14:49:40
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Oct 03, 2022 14:50:09
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Oct 03, 2022 14:50:33
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Oct 03, 2022 14:51:22
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Oct 03, 2022 17:14:21
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Oct 03, 2022 17:30:14
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Oct 07, 2022 15:32:46
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Est105
 +
|authoredOn=Nov 29, 2022 14:49:15
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 05, 2022 15:46:39
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 05, 2022 15:47:25
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 08, 2022 21:10:27
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Dec 09, 2022 13:55:38
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Dec 09, 2022 13:59:04
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Est105
 +
|authoredOn=Dec 09, 2022 21:23:59
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 13, 2022 16:09:40
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 13, 2022 21:26:13
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Dec 16, 2022 20:52:34
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Dec 16, 2022 20:55:27
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 19, 2022 21:10:36
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 19, 2022 21:12:12
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 21, 2022 15:42:23
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Dec 21, 2022 17:48:02
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:04:14
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:08:32
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Feb 06, 2023 19:12:58
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Feb 07, 2023 13:50:18
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Feb 08, 2023 14:17:31
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Feb 09, 2023 17:52:56
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Feb 13, 2023 17:27:03
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Feb 28, 2023 18:45:31
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Feb 28, 2023 18:49:15
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Mar 01, 2023 17:18:22
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Mar 01, 2023 17:40:37
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 06, 2023 17:35:37
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 06, 2023 17:36:24
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 06, 2023 17:37:06
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Td693
 +
|authoredOn=Mar 09, 2023 19:10:02
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Td693
 +
|authoredOn=Mar 09, 2023 19:10:02
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 10, 2023 13:42:13
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 10, 2023 13:58:41
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 12:59:54
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 13:00:59
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Mar 28, 2023 13:29:22
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Njc35
 +
|authoredOn=May 15, 2023 12:19:27
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Njc35
 +
|authoredOn=May 15, 2023 12:20:21
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Njc35
 +
|authoredOn=May 15, 2023 12:20:59
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=May 15, 2023 12:49:02
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=May 26, 2023 17:41:52
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 17:42:15
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 17:45:01
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 17:52:07
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 01, 2023 18:39:58
 +
}}
 +
{{status
 +
|status=active
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Jun 05, 2023 16:17:28
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Iac0
 +
|authoredOn=Jun 05, 2023 16:19:52
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 07, 2023 20:03:42
 +
}}
 +
{{status
 +
|status=submitted
 +
|identifier=WSI21-128
 +
|requester=Cfh13
 +
|authoredOn=Jun 15, 2023 14:10:05
 +
}}
 +
{{status
 +
|status=received
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 26, 2023 18:35:57
 +
}}
 +
{{status
 +
|status=scanning
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jun 26, 2023 18:36:54
 +
}}
 +
{{status
 +
|status=completed
 +
|identifier=WSI21-128
 +
|requester=Aja51
 +
|authoredOn=Jul 07, 2023 14:56:06
 
}}
 
}}

Latest revision as of 09:57, July 7, 2023


Request type Study
Subspecialty Cytology
Set Cytology
Topic Salivary Gland
Presenter MGH


Toggle columns: Diagnosis

Case Clinical history Requester Diagnosis
Case Clinical history Requester Diagnosis

Case 1


53M Em99 Mucoepidermoid carcinoma • low-grade

Case 2


40-year-old female. Left parotid mass. Iac0 Bland-appearing spindle cells • consistent with nodular fasciitis. Molecular testing confirmed USP6-rearrangement.

Case 3


22yo M with 3.1cm left submandibular mass x 3 years Mlz8 Cellular • myoepithelial-predominant pleomorphic adenoma

Case 5


72yo F with right parotid mass Mlz8 Pleomorphic adenoma

Case 6


73-year-old female. Iac0 Merkel cell carcinoma

Case 7


38-year-old female. Left temporal/supra-auricular mass. Iac0 Adenoid cystic carcinoma.

Case 8


49-year-old male. Parotid mass. Iac0 Pleomorphic adenoma • myoepithelial-rich

Case 9


59F. Left neck/mandible. History of ductal carcinoma of breast. Iac0 Salivary duct carcinoma

Case 10


60F. Parotid mass. Iac0 Atypical basaloid cells. Resection consistent with basal cell adenoma.

Case 11


69M. Parotid mass. Iac0 Bland-appearing ductal cells with abundant chronic inflammation. Resection - low-grade mucoepidermoid carcinoma with CRTC1-MAML2

Case 12


59 y/old M right parotid mass stable for several years Lcm51 Pleomorphic adenoma

Case 13


62 year old female with 1.1 x 1.4 x 1.8 cm left parotid tail mass. Mc1192 Warthin tumor

Case 14


64 year old female with left parotid mass Pab16 mucoepidermoid carcinoma

Case 15


55 year old man with a 2 year history of a parotid mass. Cfh13 Benign: Cellular pleomorphic adenoma

Case 16


58M • left parotid mass Mlz8 SALIVARY GLAND NEOPLASM OF UNCERTAIN MALIGNANT Potential (SUMP). Atypical matrix-producing neoplasm with prominent matrix globules • ddx adenoid cystic carcinoma • atypical PA • others

Case 17


73M. History of squamous cell carcinoma of temple. Iac0 Metastatic poorly differentiated squamous cell carcinoma • with focal keratinization to parotid and neck lymph node.

Case 18


45 yo F with a history of a resected salivary gland malignancy. Now presenting with a 10 cm pelvic mass. Cfh13 Metastatic adenoid cystic carcinoma.

Case 19


32F hx of Sjogren. Parotid and submandibular sialadenitis. Iac0 Eosinophilic sialadenitis (query eosinophilic sialodochitis)

Case 20


1.7 cm well circumscribed hypoechoic mass in the parotid Est105 Suspicious for malignancy • suspicious for acinic cell carcinoma

Case 21


62 yo F with a 4 year history of a growing parotid mass Cfh13 SUMP. Basaloid neoplasm with atypia. No overt features of malignant transformation.

Case 22


70 yo M • smoker • with a right parotid mass Est105 Warthin Tumor

Case 23


79 yo M never smoker • with a 1.2 cm parotid mass. Cfh13 Non-Neoplastic. Abundant amylase crystalloids with scattered inflammatory cells.

Case 24


48 yo M with incidentally identified 2 cm parotid nodule. Cfh13 Mucoepidermoid carcinoma.

Case 25


75M. Parotid mass. Iac0 Warthin tumor.

Case 26


70M. Parotid mass. Iac0 Warthin tumor.

Case 27


62F. Left parotid mass. Iac0 SUMP - basaloid neoplasm. Fusion assay negative for rearrangement. Subsequent resection - Cellular • myoepithelial-rich pleomorphic adenoma with basaloid features

Case 28


88 YO • parotid mass Td693 Oncocytic neoplasm favor oncocytoma

Case 29


67-year-old woman with 2.3 cm lesion within superficial lobe of parotid gland Njc35 Neoplasm: Benign; Warthin Tumor

Case 30


58M. Parotid mass. Iac0 Adenoid cystic carcinoma

Case 31


79 yo female Dc679 Atypical cells and amylose crystals (likely benign)

Case 32


48 yo male Dc679 Warthin tumor

Case 33


48 yo male Dc679 A. INTRAPAROTID LYMPH NODE BX RIGHT:

Warthin tumor (see comment). Comment: The small core biopsy shows columnar-lined oxyphilic epithelium with underlying lymphoid tissue composed predominantly of small lymphocytes with rare small reactive appearing germinal centers. Immunohistochemical stains show that the underlying lymphocytic infiltrate is composed of aggregates of CD20+ • CD5- B cells with intervening CD3+ CD5+ T cell rich regions. BCL2 stains most lymphocytes with a rare small germinal centers negative for BCL2. Flow cytometry is negative for a B cell lymphoproliferative disorder (see below).

The findings support a diagnosis of Warthin tumor.

Case 34


60 yo male Dc679 Secretory carcinoma

Case 139


69 yo f w/ history of carcinoma. S/p chemo and radiation with new cheek nodule. Ndk6 Mucin-producing carcinoma morphologically consistent with involvement by the patient's known primary endocrine mucin-producing sweat gland carcinoma.

Case 140


70M. Left neck LN. History of mucoepidermoid carcinoma of hard palate. Iac0 Metastatic high-grade mucoepidermoid carcinoma with CRTC1::MAML2 fusion.

Case 141


80M. Lesion of parotid gland. Iac0 Benign. Amylase crystalloids and cyst contents.

Case 142


Secretary carcinoma Sxm Secretary carcinoma

Case 143


79 year old female with history of Merkel cell carcinoma involving the left submandibular gland. Now with right submandibular lesion up to 2.0cm. Tz046 Metastatic neuroendocrine carcinoma • compatible with patient's known Merkel cell carcinoma.























































Retrieved from "https://learn.mghpathology.org/index.php?title=WSI21-128&oldid=111150"
  • Powered by MediaWiki
  • Search Powered by Cargo
  • Massachusetts General Hospital